NovoCure Shares Surge on FDA Approval for Pancreatic Cancer Device
NovoCure's stock jumped over 20% premarket after the FDA cleared its Optune Pax device for treating locally advanced pancreatic cancer, marking the first new treatment for this condition in nearly three decades.
Regulation
